

Global Market Access Compliance

Data Cutoff:
April 2026 · Based on
official releases and
authoritative industry reports



2026

Disclaimer: This document is for business decision-making reference only and does not constitute legal advice. For specific compliance requirements, refer to the latest official releases from regulatory authorities or consult professional regulatory advisors.

THREE

PATHWAYS EVOLVING

[GRAS] • [NDI] • [ODI]

What we're observing

1 GRAS self-affirmed reforms in progress

2 NDI guidance under continuous update

3 ODI list being documented

SECTION ONE USA
FDA

“ ”

Pathway selection benefits from early consideration.

We can help you assess which route aligns with your timeline and ingredient profile.



What this means for your planning



3-5 YEARS

IS THE INDUSTRY CONSENSUS TIMELINE FOR NEW HEALTH CLAIMS

What we're observing

70%+ of health claims rejected

2000+ botanical claims pending

Novel food approval: **2-3** years average

QPS list regularly updated



SECTION TWO **EU EFSA**

“ ”

If your strategy requires new claims, early planning is essential. Using existing approved claims can offer a faster route. We can help you evaluate the options.

What this means for your planning



TWO TRACKS

REGISTRATION VS FILING

What we're observing

1

Filing eligible
24 nutrients + 10
non-nutrients

2

Ginseng/American
ginseng/reishi now
eligible for filing

3

CoQ10/Melatonin/
Fish oil added to
filing

4

First new function
approved: helps
maintain bone/joint
health



SECTION CHINA THREE SAMR

“ ”

Choosing ingredients on the filing list can offer a faster track. New ingredients or functions require the registration route.

We can help you assess which path fits your product profile.

What this means for your planning

THREE TIERS

[FOSHU]

[FNFC]

[FFC]

2026 new rules in effect

FFC novel ingredients

120 business days review

GMP mandatory for natural extracts

Health harm reports

mandatory immediately



SECTION FOUR JAPAN FOUR CAA



Regular ingredients remain on a faster track via FFC.



Novel ingredients benefit from planning 6+ months.



What this means for your planning



SECTION FIVE [Industry Estimate]

GLOBAL COMPLIANCE TIMELINE



USA

Fastest Path
NDI notification: 6–12 months

Longer Path
Novel ingredient + clinical: 2–3 years

CHINA

Fastest Path
Within filing: 6–12 months

Longer Path
New ingredient registration: 2–3 years



EU

Fastest Path
Use existing claims: direct market entry

Longer Path
New health claim: 3–5 years

Japan

Fastest Path
Regular ingredient FFC: 60 business days

Longer Path
Novel ingredient FFC: 120 business days

SECTION SIX Compliance as part of your product strategy

CONSIDERATIONS FOR YOUR PLANNING



#1

Define your target markets first
different markets,
different pathways.

Explore compliance options early
some paths offer
faster entry.

#2



#3

Factor timing and budget into your roadmap
early planning helps.

Consult professionals when needed
we're here to help
navigate.

#4



SECTION SEVEN

DATA SOURCES & DISCLAIMER

Sources consulted

FDA.gov · EFSA · China SAMR · Japan CAA
SupplySide 2026 · Lexology · Food Supplements Europe
China Market Regulation News 2026 · Foodmate Law
Summary
Medical Japan Industry Insights · Industry consensus
reports

Important note

This document is based on publicly available information as of March 2026, for business reference only. Regulations may change. We recommend consulting official sources or professional advisors for specific compliance requirements applicable to your products and markets.



For more information, please
feel free to contact us.

4Unutra(Hainan) Co., Ltd

Home:www.4nuntra.com

Email:info@4unutra.com

Te1: +86 0898 6537 8036

Phone:+86 193 8998 4020

No.181 Xingyang Avenue, Jiangdong
New District,Haikou,Hainan, China

